Skip to main content
. 2015 Feb 16;13(1):94–102. doi: 10.1038/cmi.2014.131

Figure 1.

Figure 1

TRIM22 is induced in PBMCs by Type I IFN treatment of HCV patients and is associated with a decrease in HCV levels. (a) The TRIM22 mRNA level was significantly increased in the PBMCs of HCV patients approximately 12 h after initiation of IFNα treatment, as measured by real-time PCR. Comparison of the HCV mRNA levels with the baseline HCV mRNA level at the remaining time points revealed significant differences. ***P<0.001 as determined by Student's t-test. (b) HCV viral titers (shown as the logarithm) in patients' blood decreased markedly, as measured by COBAS (as described in the section on ‘Materials and methods'). Comparison of the HCV titer with the baseline virus titration at other time points revealed significant differences. ***P<0.001, as determined by Student's t-test. (c) TRIM22 is induced in patient PBMC samples, as determined by western blotting (a representative patient result is shown). HCV, hepatitis C virus; IFN, interferon; PBMC, peripheral blood mononuclear cell; TRIM, tripartite motif.